We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo

By LabMedica International staff writers
Posted on 02 Aug 2013
Abbott (Abbott Park, IL, USA) features solutions to help labs prepare for the evolving healthcare environment. More...
US healthcare providers are playing an increasingly important role in clinical labs to prevent medical errors, lower readmission rates, and improve patient care. Abbott showcased solutions designed to meet the needs of its lab customers while reducing costs and improving productivity at the American Association for Clinical Chemistry (AACC) annual meeting and clinical lab expo, July 28–August 1, 2013 in Houston (TX, USA).

Abbott also featured a variety of its solutions, including the first US Food and Drug Administration (FDA; Silver Spring, MD, USA)- approved genotyping test for hepatitis C (HCV), the RealTime HCV Genotype II test; the FDA-cleared FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System; as well as the Accelerator a3600, a laboratory automation track system.

In addition, Abbott also showcased the company’s approach to customer-focused innovation through its program called "Factoring in the Human." On its recently launched Web site (please see Related Links below). Abbott shares the company’s focus on human factor principles and customer-centric approaches to influence product design. Laboratory professionals are encouraged to visit the website to learn more.

"Clinical laboratories are looking for the right solutions to successfully address the complexities and opportunities presented by the changing healthcare environment," said Greg Ahlberg, divisional vice president, US Commercial Operations, Diagnostics, Abbott. "Abbott has one of the broadest and most flexible portfolios available today to help labs drive efficiency and optimization, leading to improved patient care."

More than 30 scientific posters and/or oral presentations related to Abbott’s solutions will be presented during the AACC program. Seventeen posters cover cardiac markers and 13 focus on the performance of several clinical chemistry assays as well as on important areas, such as transplant, endocrine, metabolic, and congenitals.

Related Links:

Abbott
Abbott - Factoring the Human
US Food and Drug Administration



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
All-in-One Molecular System
AIO M160
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.